secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001171843-26-001447
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience amends CEO pay, appoints Frost as CFO with $375k base
------------------------------------------------------------------------

- CEO John Duke gets base salary $515k; $100k cash bonus tied to credit facility refinancing.
- CEO eligible for annual cash incentive up to 80% of base; target 75k RSUs post 1:10 reverse split.
- CFO Mark Frost appointed effective March 6, 2026; salary $375k, annual cash incentive up to 60%.
- Frost's target equity grant for 2026 is 30k RSUs post reverse split; agreements run through 2027.
- Reverse stock split (1:10) takes effect March 13, 2026 as previously announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326001447/0001171843-26-001447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326001447/f8k_031026.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer